name	nt_name	aa_name	multi_aa_name	multiaa_mutation_split_names	start	vcf_gene	chrom_region	mutation_type	dp	obs_sample_size	variant_pop_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao_by_var_seq	ao	variant_seq	reference_seq	function_category	citation	citation_url	comb_mutation	function_description	heterozygosity	viral_lineages	clade_defining_status	status	voi_designation_date	voc_designation_date	vum_designation_date
c.A-3T	c.A-3T				28271	N	intergenic		29	29	29						0	T=29	29	T	A						False	C.37	C.37=True	VOI	14-Jun-2021		
c.C-25T	c.C-25T				241	orf1ab	5' UTR		29	29	29						0	T=29	29	T	C						False	C.37	C.37=True	VOI	14-Jun-2021		
p.3676del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'S3675del', 'F3677del'	11287	orf1ab	ORF1ab		58	58	29			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=58	58	G	GTCTGGTTTT						False	C.37	C.37=True	VOI	14-Jun-2021		
p.A5703A	c.C17109T	p.A5703A			17373	orf1ab	ORF1ab	SILENT	29	29	29			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	11	T=18	18	T	C						False	C.37	C.37=False	VOI	14-Jun-2021		
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	29	29	29						0	G=29	29	G	A	ACE2 receptor binding affinity	Li et al. (2020)	https://doi.org/10.1016/j.cell.2020.07.012		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	C.37	C.37=True	VOI	14-Jun-2021		
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	29	29	29						0	G=29	29	G	A	immunosuppression variant emergence	Landis et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	C.37	C.37=True	VOI	14-Jun-2021		
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	29	29	29						0	G=29	29	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	C.37	C.37=True	VOI	14-Jun-2021		
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	29	29	29						0	G=29	29	G	A	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	C.37	C.37=True	VOI	14-Jun-2021		
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	29	29	29						0	G=29	29	G	A	trafficking	Barrett et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	C.37	C.37=True	VOI	14-Jun-2021		
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	29	29	29						0	G=29	29	G	A	trafficking	Daniloski et al. (2021)	https://doi.org/10.7554/elife.65365		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	C.37	C.37=True	VOI	14-Jun-2021		
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	29	29	29						0	G=29	29	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	C.37	C.37=True	VOI	14-Jun-2021		
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	29	29	29						0	G=29	29	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	C.37	C.37=True	VOI	14-Jun-2021		
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	29	29	29						0	G=29	29	G	A	trafficking	Ozono et al. (2020)	https://www.nature.com/articles/s41467-021-21118-2		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	C.37	C.37=True	VOI	14-Jun-2021		
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	29	29	29						0	G=29	29	G	A	trafficking	Zhang et l. (2020)	https://www.nature.com/articles/s41467-020-19808-4		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	C.37	C.37=True	VOI	14-Jun-2021		
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	29	29	29						0	G=29	29	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	C.37	C.37=True	VOI	14-Jun-2021		
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	29	29	29						0	G=29	29	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	C.37	C.37=True	VOI	14-Jun-2021		
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	29	29	29						0	G=29	29	G	A	viral load	Plante et al. (2020)	https://www.nature.com/articles/s41586-020-2895-3		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	C.37	C.37=True	VOI	14-Jun-2021		
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	29	29	29						0	G=29	29	G	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	C.37	C.37=True	VOI	14-Jun-2021		
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	29	29	29						0	G=29	29	G	A	virion structure	Weissman et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	C.37	C.37=True	VOI	14-Jun-2021		
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	29	29	29						0	G=29	29	G	A	virion structure	Yurkovetskiy et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	C.37	C.37=True	VOI	14-Jun-2021		
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	29	29	29						0	G=29	29	G	A	virion structure	Zhang et al. (2020)	https://www.nature.com/articles/s41467-020-19808-4		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	C.37	C.37=True	VOI	14-Jun-2021		
p.F120F	c.C360T	p.F120F			28253	ORF8	ORF8	SILENT	29	29	29	mask	highly_homoplasic				0	T=29	29	T	C						False	C.37	C.37=True	VOI	14-Jun-2021		
p.F2387V	c.T7159G	p.F2387V			7424	orf1ab	ORF1ab	MISSENSE	29	29	29			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	G=29	29	G	T						False	C.37	C.37=True	VOI	14-Jun-2021		
p.F346F	c.C1038T	p.F346F			29311	N	N	SILENT	29	29	29						0	T=29	29	T	C						False	C.37	C.37=True	VOI	14-Jun-2021		
p.F3677del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'S3675del', '3676del'	11287	orf1ab	ORF1ab		29	29	29			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=29	29	G	GTCTGGTTTT						False	C.37	C.37=True	VOI	14-Jun-2021		
p.F490S	c.T1469C	p.F490S			23031	S	S	MISSENSE	29	29	29						0	C=29	29	C	T	ACE2 receptor binding affinity	Zahradnik et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.06.425392		Among the first selected minor variants in an in vitro evolution experiment for ACE2 binding.	False	C.37	C.37=True	VOI	14-Jun-2021		
p.F490S	c.T1469C	p.F490S			23031	S	S	MISSENSE	29	29	29						0	C=29	29	C	T	antibody epitope effects	Liu et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-32.	False	C.37	C.37=True	VOI	14-Jun-2021		
p.F490S	c.T1469C	p.F490S			23031	S	S	MISSENSE	29	29	29						0	C=29	29	C	T	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1		Complete loss of binding in ELISA by the variant against monoclonal antibody ab8	False	C.37	C.37=True	VOI	14-Jun-2021		
p.F490S	c.T1469C	p.F490S			23031	S	S	MISSENSE	29	29	29						0	C=29	29	C	T	convalescent plasma escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Strong reduction in neutralization capability of all 4 convalescent sera tested (3 ablations).	False	C.37	C.37=True	VOI	14-Jun-2021		
p.F490S	c.T1469C	p.F490S			23031	S	S	MISSENSE	29	29	29						0	C=29	29	C	T	monoclonal antibody serial passage escape	Greaney et al. (2020)	https://doi.org/10.1016/j.chom.2020.11.007		Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody	False	C.37	C.37=True	VOI	14-Jun-2021		
p.F490S	c.T1469C	p.F490S			23031	S	S	MISSENSE	29	29	29						0	C=29	29	C	T	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	C.37	C.37=True	VOI	14-Jun-2021		
p.F490S	c.T1469C	p.F490S			23031	S	S	MISSENSE	29	29	29						0	C=29	29	C	T	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Class 2/3 mAb C603 modestly selected for the emergence of this mutation in vitro.	False	C.37	C.37=True	VOI	14-Jun-2021		
p.F490S	c.T1469C	p.F490S			23031	S	S	MISSENSE	29	29	29						0	C=29	29	C	T	pharmaceutical effectiveness	Rappazzo et al. (2021)	https://science.sciencemag.org/content/371/6531/823		Greater than 10-fold rediuction of binding effeiency vs wild type for mAb LY-CoV555.	False	C.37	C.37=True	VOI	14-Jun-2021		
p.F924F	c.C2772T	p.F924F			3037	orf1ab	ORF1ab	SILENT	29	29	29			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=29	29	T	C						False	C.37	C.37=True	VOI	14-Jun-2021		
p.G214C	c.G640T	p.G214C			28913	N	N	MISSENSE	29	29	29						0	T=29	29	T	G						False	C.37	C.37=True	VOI	14-Jun-2021		
p.G3278S	c.G9832A	p.G3278S			10097	orf1ab	ORF1ab	MISSENSE	29	29	29			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	0	A=29	29	A	G						False	C.37	C.37=True	VOI	14-Jun-2021		
p.H2092Y	c.C6274T	p.H2092Y			6539	orf1ab	ORF1ab	MISSENSE	29	29	29			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	18	T=11	11	T	C						False	C.37	C.37=False	VOI	14-Jun-2021		
p.I82V	c.A244G	p.I82V			26766	M	M	MISSENSE	29	29	29						8	G=21	21	G	A						False	C.37	C.37=False	VOI	14-Jun-2021		
p.K3353R	c.A10058G	p.K3353R			10323	orf1ab	ORF1ab	MISSENSE	26	29	29			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	10	G=16	16	G	A						False	C.37	C.37=False	VOI	14-Jun-2021		
p.L124L	c.C372T	p.L124L			26894	M	M	SILENT	29	29	29						0	T=29	29	T	C						False	C.37	C.37=True	VOI	14-Jun-2021		
p.L3198L	c.C9592T	p.L3198L			9857	orf1ab	ORF1ab	SILENT	29	29	29			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	T=29	29	T	C						False	C.37	C.37=True	VOI	14-Jun-2021		
p.L3201P	c.T9602C	p.L3201P			9867	orf1ab	ORF1ab	MISSENSE	29	29	29			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	C=29	29	C	T						False	C.37	C.37=True	VOI	14-Jun-2021		
p.L452Q	c.T1355A	p.L452Q			22917	S	S	MISSENSE	29	29	29						0	A=29	29	A	T	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.07 fold	False	C.37	C.37=True	VOI	14-Jun-2021		
p.L452Q	c.T1355A	p.L452Q			22917	S	S	MISSENSE	29	29	29						0	A=29	29	A	T	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.27 fold	False	C.37	C.37=True	VOI	14-Jun-2021		
p.P13L	c.C38T	p.P13L			28311	N	N	MISSENSE	29	29	29						0	T=29	29	T	C	T cell evasion	de Silva et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1		Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).	False	C.37	C.37=True	VOI	14-Jun-2021		
p.P13L	c.C38T	p.P13L			28311	N	N	MISSENSE	29	29	29						0	T=29	29	T	C	homoplasy	Borges et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1		In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent. 	False	C.37	C.37=True	VOI	14-Jun-2021		
p.P2287S	c.C6859T	p.P2287S			7124	orf1ab	ORF1ab	MISSENSE	28	29	29			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=28	28	T	C						False	C.37	C.37=True	VOI	14-Jun-2021		
p.P4715L	c.C14144T	p.P4715L			14408	orf1ab	ORF1ab	MISSENSE	29	29	29			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	T=29	29	T	C						False	C.37	C.37=True	VOI	14-Jun-2021		
p.R246_D253delinsN	c.737_757delGAAGTTATTTGACTCCTGGTG	p.R246_D253delinsN			22298	S	S		11	29	29						1	A=10	10	A	AGAAGTTATTTGACTCCTGGTG						False	C.37	C.37=True	VOI	14-Jun-2021		
p.RG203KR	c.GGG608_610AAC	p.RG203KR			28881	N	N		29	29	29						0	AAC=29	29	AAC	GGG						False	C.37	C.37=True	VOI	14-Jun-2021		
p.S3675del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'3676del', 'F3677del'	11287	orf1ab	ORF1ab		29	29	29			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=29	29	G	GTCTGGTTTT						False	C.37	C.37=True	VOI	14-Jun-2021		
p.T1246I	c.C3737T	p.T1246I			4002	orf1ab	ORF1ab	MISSENSE	29	29	29			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=29	29	T	C						False	C.37	C.37=True	VOI	14-Jun-2021		
p.T3255I	c.C9764T	p.T3255I			10029	orf1ab	ORF1ab	MISSENSE	29	29	29			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	T=29	29	T	C						False	C.37	C.37=True	VOI	14-Jun-2021		
p.T366I	c.C1097T	p.T366I			29370	N	N	MISSENSE	18	29	29						1	T=17	17	T	C						False	C.37	C.37=True	VOI	14-Jun-2021		
p.T63_T76delinsI	c.CTTGGTTCCATGCTATACATGTCTCTGGGACCAATGGTAC188_227T	p.T63_T76delinsI			21750	S	S		29	29	29						0	T=2, CTTGGTTCCATGCTATACATGTCTCTGGGACCAATGTTAT=27	2,27	T,CTTGGTTCCATGCTATACATGTCTCTGGGACCAATGTTAT	CTTGGTTCCATGCTATACATGTCTCTGGGACCAATGGTAC						False	C.37	C.37=True	VOI	14-Jun-2021		
p.T723T	c.C2169T	p.T723T			23731	S	S	SILENT	29	29	29						0	T=29	29	T	C						False	C.37	C.37=True	VOI	14-Jun-2021		
p.T859N	c.C2576A	p.T859N			24138	S	S	MISSENSE	29	29	29						0	A=29	29	A	C						False	C.37	C.37=True	VOI	14-Jun-2021		
p.Y4424Y	c.C13272T	p.Y4424Y			13536	orf1ab	ORF1ab	SILENT	58	58	29			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	T=58	58	T	C						False	C.37	C.37=True	VOI	14-Jun-2021		
p.Y5541Y	c.C16623T	p.Y5541Y			16887	orf1ab	ORF1ab	SILENT	29	29	29	mask	highly_homoplasic	helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	24	T=5	5	T	C						False	C.37	C.37=False	VOI	14-Jun-2021		
